Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical Pharmacology

Zineh, 2017, Improving the tools of clinical pharmacology: goals for 2017 and beyond, Clin Pharmacol Ther, 101, 22, 10.1002/cpt.530 Huang, 2013, The utility of modeling and simulation in drug development and regulatory review, J Pharm Sci, 102, 2912, 10.1002/jps.23570 Guo, 2018, Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and PBPK modeling approaches, Clin Pharmacol Ther, 104, 865, 10.1002/cpt.1183 Nijsen, 2018, Preclinical QSP modeling in the pharmaceutical industry: an IQ consortium survey examining the current landscape, CPT Pharmacometrics Syst Pharmacol, 7, 135, 10.1002/psp4.12282 2018 Zhao, 2012, Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions, Clin Pharmacol Ther, 92, 17, 10.1038/clpt.2012.68 Zhao, 2011, Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review, Clin Pharmacol Ther, 89, 259, 10.1038/clpt.2010.298 Wagner, 2015, Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK, CPT Pharmacometrics Syst Pharmacol, 4, 226, 10.1002/psp4.33 Jones, 2015, Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective, Clin Pharmacol Ther, 97, 247, 10.1002/cpt.37 Wagner, 2015, Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the U.S. Food and Drug Administration, Clin Pharmacokinet, 54, 117, 10.1007/s40262-014-0188-4 Wagner, 2016, Predicting the effect of CYP3A inducers on the pharmacokinetics of substrate drugs using physiologically based pharmacokinetic (PBPK) modeling: an analysis of PBPK submissions to the US FDA, Clin Pharmacokinet, 55, 475, 10.1007/s40262-015-0330-y Baneyx, 2014, Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration, Eur J Pharm Sci, 56, 1, 10.1016/j.ejps.2014.02.002 Almond, 2016, Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model, Drug Metab Dispos, 44, 821, 10.1124/dmd.115.066845 Yamashita, 2013, Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data, PLoS One, 8, e70330, 10.1371/journal.pone.0070330 Fahmi, 2016, Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective, Drug Metab Dispos, 44, 1720, 10.1124/dmd.116.071076 2017 2017 Han, 2013, Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes, Mol Pharmacol, 84, 182, 10.1124/mol.112.084517 Giacomini, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028 Galetin, 2017, Physiologically based pharmacokinetic modeling of drug transporters to facilitate individualized dose prediction, J Pharm Sci, 106, 2204, 10.1016/j.xphs.2017.03.036 Pan, 2016, The application of physiologically based pharmacokinetic modeling to predict the role of drug transporters: scientific and regulatory perspectives, J Clin Pharmacol, 56, S122, 10.1002/jcph.740 2014 2014 2017 Nigam, 2015, What do drug transporters really do?, Nat Rev Drug Discov, 14, 29, 10.1038/nrd4461 Gertz, 2013, Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential, Pharm Res, 30, 761, 10.1007/s11095-012-0918-y Zhou, 2018, Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children, Clin Pharmacol Ther, 104, 188, 10.1002/cpt.905 Calvier, 2017, Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade?, Clin Pharmacokinet, 56, 273, 10.1007/s40262-016-0436-x Green, 2018, Pediatric drug development: outlook for science-based innovation, Clin Pharmacol Ther, 103, 376, 10.1002/cpt.1001 Hsueh, 2018, PBPK modeling of the effect of reduced kidney function on the pharmacokinetics of drugs excreted renally by organic anion transporters, Clin Pharmacol Ther, 103, 485, 10.1002/cpt.750 Tan, 2018, Use of physiologically-based pharmacokinetic (PBPK) modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates, Clin Pharmacol Ther Tan, 2018, Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP, Clin Pharmacol Ther, 103, 854, 10.1002/cpt.807 Hsu, 2014, Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations, Clin Pharmacokinet, 53, 283, 10.1007/s40262-013-0117-y Scotcher, 2017, Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations, J Pharmacol Exp Ther, 360, 484, 10.1124/jpet.116.237438 2018